175 related articles for article (PubMed ID: 15876401)
21. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems.
Wang D; Miller S; Sima M; Kopecková P; Kopecek J
Bioconjug Chem; 2003; 14(5):853-9. PubMed ID: 13129387
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
Freedman OC; Amir E; Clemons MJ
Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
Toussaint ND; Elder GJ; Kerr PG
Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
[TBL] [Abstract][Full Text] [Related]
24. Polymer therapeutics: concepts and applications.
Haag R; Kratz F
Angew Chem Int Ed Engl; 2006 Feb; 45(8):1198-215. PubMed ID: 16444775
[TBL] [Abstract][Full Text] [Related]
25. Development of Bone Targeting Drugs.
Stapleton M; Sawamoto K; Alméciga-Díaz CJ; Mackenzie WG; Mason RW; Orii T; Tomatsu S
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28644392
[TBL] [Abstract][Full Text] [Related]
26. Peptide-based delivery to bone.
Aoki K; Alles N; Soysa N; Ohya K
Adv Drug Deliv Rev; 2012 Sep; 64(12):1220-38. PubMed ID: 22709649
[TBL] [Abstract][Full Text] [Related]
27. Osteotropic Peptide that differentiates functional domains of the skeleton.
Wang D; Miller SC; Shlyakhtenko LS; Portillo AM; Liu XM; Papangkorn K; Kopecková P; Lyubchenko Y; Higuchi WI; Kopecek J
Bioconjug Chem; 2007; 18(5):1375-8. PubMed ID: 17705416
[TBL] [Abstract][Full Text] [Related]
28. Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes.
Gittens SA; Bansal G; Kucharski C; Borden M; Uludag H
Mol Pharm; 2005; 2(5):392-406. PubMed ID: 16196492
[TBL] [Abstract][Full Text] [Related]
29. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery).
Bessa PC; Casal M; Reis RL
J Tissue Eng Regen Med; 2008; 2(2-3):81-96. PubMed ID: 18383454
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates-much more than only drugs for bone diseases.
Kuźnik A; Październiok-Holewa A; Jewula P; Kuźnik N
Eur J Pharmacol; 2020 Jan; 866():172773. PubMed ID: 31705903
[TBL] [Abstract][Full Text] [Related]
31. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
33. Silica xerogels and hydroxyapatite nanocrystals for the local delivery of platinum-bisphosphonate complexes in the treatment of bone tumors: a mini-review.
Iafisco M; Margiotta N
J Inorg Biochem; 2012 Dec; 117():237-47. PubMed ID: 22824154
[TBL] [Abstract][Full Text] [Related]
34. Nanotechnology controlled drug delivery for treating bone diseases.
Yang L; Webster TJ
Expert Opin Drug Deliv; 2009 Aug; 6(8):851-64. PubMed ID: 19637973
[TBL] [Abstract][Full Text] [Related]
35. Selectivity in bone targeting with multivalent dendritic polyanion dye conjugates.
Gröger D; Kerschnitzki M; Weinhart M; Reimann S; Schneider T; Kohl B; Wagermaier W; Schulze-Tanzil G; Fratzl P; Haag R
Adv Healthc Mater; 2014 Mar; 3(3):375-85. PubMed ID: 23996966
[TBL] [Abstract][Full Text] [Related]
36. Targeting therapeutics to bone by conjugation with bisphosphonates.
Young RN; Grynpas MD
Curr Opin Pharmacol; 2018 Jun; 40():87-94. PubMed ID: 29626715
[TBL] [Abstract][Full Text] [Related]
37. Bisphosphonate treatment of pediatric bone disease.
Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
[TBL] [Abstract][Full Text] [Related]
38. Biomedical applications of bisphosphonates.
Giger EV; Castagner B; Leroux JC
J Control Release; 2013 Apr; 167(2):175-88. PubMed ID: 23395668
[TBL] [Abstract][Full Text] [Related]
39. A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone.
Bansal G; Wright JE; Kucharski C; Uludağ H
Angew Chem Int Ed Engl; 2005 Jun; 44(24):3710-4. PubMed ID: 15880536
[No Abstract] [Full Text] [Related]
40. An insight on hyaluronic acid in drug targeting and drug delivery.
Yadav AK; Mishra P; Agrawal GP
J Drug Target; 2008 Feb; 16(2):91-107. PubMed ID: 18274931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
